PolyNovo Limited provide an update on its hernia device and path to market. Syntrel is new novel hernia device composed of NovoSorb foam that is ultrasonically welded to a new NovoSorb film to create a 100% bioabsorbable hernia repair device. The film provides strength to the repaired hernia whilst the foam promotes native tissue regeneration within the foam scaffold. PolyNovo has commenced a pre-clinical study in the US to demonstrate bio-absorption rates, biocompatibility, toxicology profile, and efficacy in hernia repair. This study will provide progressive data at three-month intervals. PolyNovo is assisted by two external regulatory consultants and advice from the US FDA, to ensure The company has sufficient data to submit a strong dossier supporting hernia applications. Data generated from this study will also support future product filings that utilise the NovoSorb technology. Unlike the film used on NovoSorb BTM, which requires delamination, the NovoSorb film and NovoSorb foam are designed to be absorbed in the body. The Syntrel device will provide reinforcement to the hernia repair site, allowing for optimal tissue regeneration. The resorbable NovoSorb film was originally developed to provide sufficient long-term mechanical strength for Syntrel, but will also be deployed in a portfolio of other hernia repair devices, as well as future product applications including breast reconstruction, sports medicine, and other clinical applications where mechanical strength is a key requirement. Syntrel product for the trials and beyond is being manufactured at the company's Port Melbourne facility.